Sanguine Corp. (SGUI.OB) Receives Notable Purchase Order from Virginia Commonwealth University
Biopharmaceutical company Sanguine Corp. develops products for biomedical and medical device applications. The company today announced a “significant” purchase order from Virginia Commonwealth University (VCU) for PHER-O2, Sanguine’s ultra-oxygen carrying perfluorocarbon-based product. Shares of SGUI soared 30 percent to $.39 on word of the purchase. VCU is nationally recognized for its research in groundbreaking work using perfluorocarbons (PFCs); applications of perfluorocarbons include eye surgery, imaging, liquid ventilation, artificial blood and treatment of decompression sickness, as well as various other non-medical applications. VCU contracts are part of several current U.S. Federal Government funded projects, and are backed by millions of dollars…